Oculis Accelerates Enrollment in both DIAMOND Phase 3 Trials of OCS-01 in Diabetic Macular Edema and Expands its DIAMOND Program Committees
Oculis Holding AG (Nasdaq: OCS) announces accelerated patient enrollment for both Phase 3 DIAMOND trials of OCS-01 eye drops in diabetic macular edema (DME). The DIAMOND-1 trial has enrolled ~70% of patients, while DIAMOND-2 has enrolled ~40%. The company has also expanded its DIAMOND program committees with globally renowned retina experts.
The DIAMOND program consists of two Phase 3, double-masked, randomized, multi-center trials evaluating the efficacy and safety of OCS-01 eye drops in DME patients. If approved, OCS-01 has the potential to be the first topical eye drop to treat DME, potentially transforming the treatment paradigm.
Dr. Arshad M. Khanani, DIAMOND Program Steering Committee Chairperson, highlighted promising results from Stage 1 of the DIAMOND Phase 3 program, showing significant improvements in visual acuity and clinically meaningful reduction in macular edema for patients treated with OCS-01.
Oculis Holding AG (Nasdaq: OCS) annuncia un'accelerazione nell'arruolamento dei pazienti per entrambe le sperimentazioni DIAMOND di Fase 3 relative alle gocce oculari OCS-01 per l'edema maculare diabetico (DME). La sperimentazione DIAMOND-1 ha arruolato circa il 70% dei pazienti, mentre la DIAMOND-2 ha arruolato circa il 40%. Inoltre, l'azienda ha ampliato i comitati del programma DIAMOND con esperti di retina di fama mondiale.
Il programma DIAMOND consiste in due prove di Fase 3, doppio cieco, randomizzate e multicentriche, che valutano l'efficacia e la sicurezza delle gocce oculari OCS-01 nei pazienti con DME. Se approvato, OCS-01 potrebbe diventare la prima goccia oculare topica per il trattamento del DME, trasformando potenzialmente il paradigma terapeutico.
Il Dr. Arshad M. Khanani, presidente del Comitato Direttivo del Programma DIAMOND, ha evidenziato risultati promettenti dalla Fase 1 del programma DIAMOND di Fase 3, mostrando miglioramenti significativi nell'acuit脿 visiva e una riduzione clinicamente significativa dell'edema maculare per i pazienti trattati con OCS-01.
Oculis Holding AG (Nasdaq: OCS) anuncia un acelerado reclutamiento de pacientes para ambos ensayos de Fase 3 DIAMOND de las gotas oculares OCS-01 en edema macular diab茅tico (DME). El ensayo DIAMOND-1 ha reclutado aproximadamente el 70% de los pacientes, mientras que el DIAMOND-2 ha reclutado alrededor del 40%. La compa帽铆a tambi茅n ha ampliado sus comit茅s del programa DIAMOND con expertos en retina de renombre mundial.
El programa DIAMOND consiste en dos ensayos de Fase 3, doble ciego, aleatorizados y multic茅ntricos que eval煤an la eficacia y seguridad de las gotas oculares OCS-01 en pacientes con DME. Si se aprueba, OCS-01 podr铆a convertirse en la primera gota ocular t贸pica para tratar el DME, transformando potencialmente el paradigma del tratamiento.
El Dr. Arshad M. Khanani, presidente del Comit茅 Directivo del Programa DIAMOND, destac贸 resultados prometedores de la Fase 1 del programa DIAMOND de Fase 3, mostrando mejoras significativas en la agudeza visual y una reducci贸n cl铆nicamente significativa del edema macular en los pacientes tratados con OCS-01.
Oculis Holding AG (Nasdaq: OCS)电� 雼闺嚚氤戩劚 頇╇皹攵�膦�(DME)鞐� 雽�頃� OCS-01 鞝愳晥鞎�鞚� 霊� 臧滌潣 3靸� DIAMOND 鞁滍棙鞐� 雽�頃� 頇橃瀽 霌彪鞚� 臧�靻嶍檾頃滊嫟瓿� 氚滍憸頄堨姷雼堧嫟. DIAMOND-1 鞁滍棙鞚� 鞎� 70%鞚� 頇橃瀽毳� 霌彪頄堨溂氅�, DIAMOND-2 鞁滍棙鞚� 鞎� 40%鞚� 頇橃瀽毳� 霌彪頄堨姷雼堧嫟. 霕愴暅, 鞚� 須岇偓電� 靹戈硠鞝侅溂搿� 鞙犽獏頃� 毵濍 鞝勲臧�霌り臣 頃粯 DIAMOND 頂勲攴鸽灗 鞙勳洂須岆ゼ 頇曥灔頄堨姷雼堧嫟.
DIAMOND 頂勲攴鸽灗鞚� DME 頇橃瀽鞐愳劀 OCS-01 鞝愳晥鞎§潣 須姤瓿� 鞎堨爠靹膘潉 韽夑皜頃橂姅 3靸� 鞚挫 毵龟瞼 氍挫瀾鞙� 雼れ劶韯� 鞁滍棙 霊� 臧滊 甑劚霅橃柎 鞛堨姷雼堧嫟. 毵岇暯 鞀轨澑鞚� 霅� 瓴届毎, OCS-01鞚� DME 旃橂毳� 鞙勴暅 斓滌磮鞚� 甑唽 鞝愳晥鞎§澊 霅� 靾� 鞛堨溂氅�, 旃橂 韺煬雼れ瀯鞐� 順侅嫚鞚� 臧�鞝胳槵 臧�電レ劚鞚� 鞛堨姷雼堧嫟.
DIAMOND 頂勲攴鸽灗 鞖挫榿鞙勳洂須� 鞚橃灔鞚� Dr. Arshad M. Khanani電� DIAMOND 3靸� 頂勲攴鸽灗鞚� 1雼硠鞐愳劀 鞙犽頃� 瓴瓣臣毳� 臧曥“頃橂┌, OCS-01搿� 旃橂氚涭潃 頇橃瀽霌れ棎瓴� 鞁滊牓 頄レ儊瓿� 鞛勳儊鞝侅溂搿� 鞚橂 鞛堧姅 頇╇皹攵�膦� 臧愳唽臧� 鞛堨潓鞚� 氤挫棳欤检棃鞀惦媹雼�.
Oculis Holding AG (Nasdaq: OCS) annonce une acc茅l茅ration de l'enr么lement des patients pour les deux essais DIAMOND de phase 3 portant sur les gouttes oculaires OCS-01 dans le cas de l'艙d猫me maculaire diab茅tique (DME). L'essai DIAMOND-1 a enr么l茅 environ 70 % des patients, tandis que le DIAMOND-2 a enregistr茅 environ 40 % des patients. L'entreprise a 茅galement 茅largi ses comit茅s du programme DIAMOND avec des experts en r茅tine de renomm茅e mondiale.
Le programme DIAMOND comprend deux essais de phase 3, en double aveugle, randomis茅s et multicentriques, qui 茅valuent l'efficacit茅 et la s茅curit茅 des gouttes oculaires OCS-01 chez les patients atteints de DME. Si elles sont approuv茅es, les OCS-01 pourraient devenir les premi猫res gouttes oculaires topiques pour traiter le DME, transformant potentiellement le paradigme de traitement.
Le Dr Arshad M. Khanani, pr茅sident du comit茅 directeur du programme DIAMOND, a soulign茅 les r茅sultats prometteurs de la phase 1 du programme DIAMOND de phase 3, montrant des am茅liorations significatives de l'acuit茅 visuelle et une r茅duction cliniquement significative de l'艙d猫me maculaire chez les patients trait茅s avec OCS-01.
Oculis Holding AG (Nasdaq: OCS) k眉ndigt eine beschleunigte Rekrutierung von Patienten f眉r beide Phase-3-DIAMOND-Studien der OCS-01-Augentropfen bei diabetischem Makula枚dem (DME) an. In der Studie DIAMOND-1 wurden etwa 70 % der Patienten rekrutiert, w盲hrend in der DIAMOND-2-Studie etwa 40 % der Patienten rekrutiert wurden. Das Unternehmen hat auch seine DIAMOND-Programmaussch眉sse mit weltweit anerkannten Experten f眉r Netzhauterkrankungen erweitert.
Das DIAMOND-Programm besteht aus zwei Phase-3-Studien, die doppelt maskiert, randomisiert und multizentrisch durchgef眉hrt werden und die Wirksamkeit und Sicherheit von OCS-01-Augentropfen bei DME-Patienten bewerten. Bei Genehmigung k枚nnte OCS-01 das erste topische Augentropfen zur Behandlung von DME werden und so das Behandlungsparadigma potenziell revolutionieren.
Dr. Arshad M. Khanani, Vorsitzender des Lenkungsausschusses des DIAMOND-Programms, hob die vielversprechenden Ergebnisse aus Phase 1 des DIAMOND-Programms der Phase 3 hervor, die signifikante Verbesserungen der Sehsch盲rfe und eine klinisch relevante Reduktion des Makula枚dems bei Patienten zeigten, die mit OCS-01 behandelt wurden.
- Accelerated patient enrollment in both Phase 3 DIAMOND trials
- ~70% of patients enrolled in DIAMOND-1 trial
- ~40% of patients enrolled in DIAMOND-2 trial
- Expansion of DIAMOND program committees with renowned retina experts
- Promising Stage 1 results showing significant improvements in visual acuity and macular edema reduction
- None.
Insights
The acceleration of patient enrollment in Oculis' DIAMOND Phase 3 trials for OCS-01 in diabetic macular edema (DME) is a significant development. With ~70% enrollment in DIAMOND-1 and ~40% in DIAMOND-2, the company is making rapid progress towards completing these pivotal studies.
The potential of OCS-01 as the first topical eye drop for DME could be revolutionary. Current DME treatments often involve invasive injections, so a non-invasive option could greatly improve patient experience and potentially increase treatment adherence.
The expansion of the DIAMOND program committees with renowned retina experts adds credibility and expertise to the trials. This could enhance the quality of the study design and interpretation of results, potentially increasing the likelihood of regulatory approval if the data is positive.
While promising, it's important to note that Phase 3 results are still pending. Investors should monitor for efficacy and safety data, as well as any signals on potential market positioning against existing DME treatments.
Oculis' accelerated enrollment in the DIAMOND trials is a positive signal for investors, potentially shortening the timeline to potential commercialization. Faster enrollment could lead to earlier data readouts and, if positive, a quicker path to market.
The DME market is substantial, with millions affected worldwide. If approved, OCS-01 could capture a significant portion of this market, especially as a first-in-class topical treatment. This represents a considerable revenue opportunity for Oculis.
However, investors should consider that Oculis, with a market cap of
The expanded expert committee, while beneficial for the trial, also indicates ongoing R&D expenses. Investors should monitor cash burn rates and potential need for future financing as the trials progress.
Overall, this news suggests positive momentum in Oculis' lead program, which could drive investor interest and potentially impact stock performance in the near term.
- Phase 3 DIAMOND-1 and DIAMOND-2 trials enrollment of OCS-01 in diabetic macular edema (DME) accelerated with great momentum
- DIAMOND program committees expanded with globally renowned retina experts
- If approved, OCS-01 has the potential to transform the treatment paradigm as the first topical eye drop to treat DME
ZUG, Switzerland, Oct. 21, 2024 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS) (鈥淥culis鈥�), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today announces the acceleration of patient enrollment for both Phase 3 DIAMOND trials of OCS-01 eye drops in DME and expansion of the DIAMOND program committees with globally renowned retina experts.
Substantial enrollment progress was achieved since the end of Q2 2024 through early October, with ~
Arshad M. Khanani, M.D., M.A, FASRS, DIAMOND Program Steering Committee Chairperson, Oculis Board of Directors member, Scientific Advisory Board Chair of Retina and Director of Clinical Research at Sierra Eye Associates, commented: 鈥淚 am honored to chair the DIAMOND steering committee, comprised of leading experts from around the globe, as we support the outstanding team at Oculis in the late-stage development of OCS-01. The results from Stage 1 of the DIAMOND Phase 3 program are promising, showing that patients treated with OCS-01 experienced significant improvements in visual acuity and a clinically meaningful reduction in macular edema. The DIAMOND program offers hope to the millions worldwide affected by DME, with OCS-01 potentially emerging as the first non-invasive topical eye drop therapy.鈥�
Riad Sherif, M.D., Chief Executive Officer of Oculis, said: 鈥漌e are very pleased with the strong momentum in patient enrollment in DIAMOND-1 and DIAMOND-2 Phase 3 trials which continues to exceed our expectations. We are also honored to have such a distinguished and broad group of global experts on the expanded DIAMOND program committees and look forward to working with the committees and benefiting from their deep expertise as we advance the DIAMOND program.鈥�
The DIAMOND program committees are comprised of world-renowned experts who provide strategic oversight as Oculis develops OCS-01 which has the potential to be the first topical eye drop to transform DME treatment paradigm:
- Arshad Khanani, M.D.
- David Almeida, M.D.
- Mark Barakat, M.D.
- Kirk Bateman, M.Sc.
- David Boyer, M.D.
- Margaret Chang, M.D.
- Saradha Chexal, M.D.
- Carl Danzig, M.D.
- Dilsher Dhoot, M.D.
- Diana Do, M.D.
- Frank Holz, M.D.
- Baruch D. Kuppermann, M.D.
- Timothy Lai, M.D.
- Anat Loewenstein, M.D.
- Sabri Markabi, M.D.
- Patricio Schlottmann, M.D.
- Ashish Sharma, M.D.
- Veeral Sheth, M.D.
- Michael Singer, M.D.
- Thomas Wolfensberger, M.D.
For more information about the DIAMOND program committee members, please visit .
To learn more about the Phase 3 DIAMOND trials, please visit .
About OCS-01 eye drops and the OPTIREACH庐听迟别肠丑苍辞濒辞驳测
Leveraging Oculis鈥� proprietary technology, OCS-01 is an OPTIREACH庐 formulation of high concentration dexamethasone eye drop. It was developed to treat the retina via an eye drop, a route of administration for DME that contrasts with currently available therapies, all requiring invasive delivery to reach the retina such as intravitreal injections or ocular implants. The OPTIREACH庐听solubilizing formulation technology addresses the main limitations of conventional eye drops by improving the solubility of lipophilic drugs, increasing the residence time on the eye surface and thereby, enabling the drug passage from the eye surface to the posterior segment of the eye. Oculis鈥� OCS-01 is developed with the aim to transform the current treatment paradigm in DME as a non-invasive topical treatment option.
OCS-01 is an investigational drug that has not received regulatory approval for commercial use in any country.
About the Phase 3 DIAMOND Program of OCS-01 in Diabetic Macular Edema
The DIAMOND-1 (DIAbetic Macular edema patients ON a Drop) and DIAMOND-2 trials are Phase 3, double-masked, randomized, multi-center trials which will evaluate the efficacy and safety of OCS-01 eye drops in patients with DME. Oculis aims to enroll 350 patients in each of these pivotal trials that will be randomized 1:1 to receive OCS-01 or vehicle six times daily for the 6-week induction phase and then three times daily through week 52 for the maintenance phase. The primary endpoint is change in best corrected visual acuity early treatment diabetic retinopathy study (BCVA ETDRS) letter score at Week 52. Secondary endpoints include percentage of patients with 鈮�15-letter gain in BCVA and change in central subfield thickness (CST), both at Week 52. Both trials were initiated upon the positive findings from stage 1 of the DIAMOND program, which was announced in the second quarter of 2023, and both trials are currently enrolling.
About Diabetic Macular Edema (DME)
DME is the leading cause of visual loss and legal blindness in patients with diabetes. Currently, it is estimated to affect around 37 million people worldwide and, with the rise of diabetes, the prevalence is expected to increase to 53 million by 20401,2. DME is an irreversible and progressive complication of diabetic retinopathy and is related to consistently having high blood sugar levels that damage nerves and blood vessels in the macula, the area of the retina responsible for sharp vision. DME occurs when blood vessels in the retina swell, and then leak, leading to a fluid build-up (edema) into the retina. There remains a significant need for safer, more effective, longer lasting, and less burdensome treatments for DME patients.
About Oculis
Oculis is a global biopharmaceutical company (Nasdaq: OCS; XICE: OCS) purposefully driven to save sight and improve eye care. Oculis鈥� highly differentiated pipeline comprises multiple innovative product candidates in development. It includes OCS-01, a topical eye drop candidate for diabetic macular edema (DME) and for the treatment of inflammation and pain following cataract surgery; licaminlimab (OCS-02), a topical biologic anti-TNF伪 eye drop candidate for dry eye disease (DED) and for non-infectious anterior uveitis; and OCS-05, a neuroprotective candidate for acute optic neuritis (AON). Headquartered in Switzerland and with operations in the U.S. and Iceland, Oculis鈥� goal is to improve the health and quality of life of patients worldwide. The company is led by an experienced management team with a successful track record and is supported by leading international healthcare investors.
For more information, please visit:
(1) Yau et al. Global Prevalence and Major Risk Factors of Diabetic Retinopathy, Diabetes Care 2012 Mar; 35(3): 556-564
(2)聽International Diabetes Federation聽鈥撀�聽Estimated diabetes prevalence worldwide in 2021: 537m, reaching 783m in 2045
Oculis Contacts
Ms. Sylvia Cheung, CFO
Investor & Media Relations
LifeSci Advisors
Corey Davis, Ph.D.
1-212-915-2577
Cautionary Statement Regarding Forward Looking Statements
This press release contains forward-looking statements and information. For example, statements regarding the potential benefits of OCS-01, including patient impact and market opportunity; the potential of OCS-01 to become the first non-invasive eye drop therapy for DME; the potential of OCS-01 to treat both front and back of the eye indications; expected future milestones and catalysts; the initiation, timing, progress and results of Oculis鈥� clinical trials, including the progress of Oculis鈥� DIAMOND Phase 3 program with OCS-01 in DME; Oculis鈥� research and development programs, regulatory and business strategy, future development plans, and management; and Oculis鈥� ability to advance product candidates into, and successfully complete, clinical trials, are forward-looking. All forward-looking statements are based on estimates and assumptions that, while considered reasonable by Oculis and its management, are inherently uncertain and are inherently subject to risks, variability and contingencies, many of which are beyond Oculis鈥� control. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on by an investor as, a guarantee, assurance, prediction or definitive statement of a fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. All forward-looking statements are subject to risks, uncertainties and other factors that may cause actual results to differ materially from those that we expected and/or those expressed or implied by such forward-looking statements. Forward-looking statements are subject to numerous conditions, many of which are beyond the control of Oculis, including those set forth in the Risk Factors section of Oculis鈥� annual report on Form 20-F and any other documents filed with the聽U.S. Securities and Exchange Commission聽(the 鈥淪EC鈥�). Copies of these documents are available on the SEC鈥檚 website,聽. Oculis undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.
FAQ
What is the current enrollment status of Oculis' DIAMOND trials for OCS-01 (OCS)?
What is the potential impact of OCS-01 (OCS) in treating diabetic macular edema?
What were the results from Stage 1 of the DIAMOND Phase 3 program for OCS-01 (OCS)?
Who is chairing the DIAMOND program steering committee for Oculis (OCS)?
